AU2022315058A1 - Compounds and compositions for the treatment of coronaviral related diseases - Google Patents
Compounds and compositions for the treatment of coronaviral related diseases Download PDFInfo
- Publication number
- AU2022315058A1 AU2022315058A1 AU2022315058A AU2022315058A AU2022315058A1 AU 2022315058 A1 AU2022315058 A1 AU 2022315058A1 AU 2022315058 A AU2022315058 A AU 2022315058A AU 2022315058 A AU2022315058 A AU 2022315058A AU 2022315058 A1 AU2022315058 A1 AU 2022315058A1
- Authority
- AU
- Australia
- Prior art keywords
- isoquinolin
- carbonitrile
- oxoimidazolidine
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224793P | 2021-07-22 | 2021-07-22 | |
| US63/224,793 | 2021-07-22 | ||
| US202163289009P | 2021-12-13 | 2021-12-13 | |
| US63/289,009 | 2021-12-13 | ||
| PCT/IB2022/056712 WO2023002409A1 (en) | 2021-07-22 | 2022-07-20 | Compounds and compositions for the treatment of coronaviral related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022315058A1 true AU2022315058A1 (en) | 2024-02-08 |
Family
ID=82742919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022315058A Pending AU2022315058A1 (en) | 2021-07-22 | 2022-07-20 | Compounds and compositions for the treatment of coronaviral related diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250092016A1 (https=) |
| EP (1) | EP4373814A1 (https=) |
| JP (1) | JP2024527424A (https=) |
| KR (1) | KR20240038996A (https=) |
| AU (1) | AU2022315058A1 (https=) |
| CA (1) | CA3226758A1 (https=) |
| MX (1) | MX2024000986A (https=) |
| PY (1) | PY2261702A (https=) |
| TW (1) | TW202321210A (https=) |
| UY (1) | UY39863A (https=) |
| WO (1) | WO2023002409A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| JP7624093B2 (ja) | 2022-04-08 | 2025-01-29 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物 |
| WO2024031089A1 (en) | 2022-08-05 | 2024-02-08 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
| WO2025125695A2 (en) * | 2024-12-17 | 2025-06-19 | Medchemica Consultancy Ltd | Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1200825B (de) * | 1962-01-13 | 1965-09-16 | Hoechst Ag | Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen |
| WO2010149755A1 (en) * | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
-
2022
- 2022-07-19 UY UY0001039863A patent/UY39863A/es unknown
- 2022-07-19 TW TW111127023A patent/TW202321210A/zh unknown
- 2022-07-19 PY PY202202261702A patent/PY2261702A/es unknown
- 2022-07-20 CA CA3226758A patent/CA3226758A1/en active Pending
- 2022-07-20 EP EP22748094.4A patent/EP4373814A1/en active Pending
- 2022-07-20 MX MX2024000986A patent/MX2024000986A/es unknown
- 2022-07-20 WO PCT/IB2022/056712 patent/WO2023002409A1/en not_active Ceased
- 2022-07-20 KR KR1020247005669A patent/KR20240038996A/ko active Pending
- 2022-07-20 JP JP2024503613A patent/JP2024527424A/ja active Pending
- 2022-07-20 AU AU2022315058A patent/AU2022315058A1/en active Pending
- 2022-07-20 US US18/580,986 patent/US20250092016A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024000986A (es) | 2024-02-12 |
| PY2261702A (es) | 2023-06-14 |
| TW202321210A (zh) | 2023-06-01 |
| KR20240038996A (ko) | 2024-03-26 |
| US20250092016A1 (en) | 2025-03-20 |
| UY39863A (es) | 2023-02-28 |
| EP4373814A1 (en) | 2024-05-29 |
| CA3226758A1 (en) | 2023-01-26 |
| WO2023002409A1 (en) | 2023-01-26 |
| JP2024527424A (ja) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250092016A1 (en) | Compounds and compositions for the treatment of coronaviral related diseases | |
| AU2018221812B2 (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| JP7097373B2 (ja) | キナーゼ阻害剤としてのアミノトリアゾロピリジン | |
| JP6388991B2 (ja) | キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド | |
| CN104922128B (zh) | 流感病毒复制抑制剂 | |
| US10508113B2 (en) | Inhibitors of tyrosine kinase 2 mediated signaling | |
| JP7471348B2 (ja) | ブルトン型チロシンキナーゼの阻害剤及びその使用方法 | |
| TWI594997B (zh) | 流感病毒複製之抑制劑 | |
| WO2022224223A1 (en) | Compounds and compositions for the treatment of coronaviral related diseases | |
| WO2016024185A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase | |
| RS58245B1 (sr) | Kombinacija derivata pirolo[2,3-d]pirimidina sa jednim ili više dodatnih sredstava kao inhibitor janus kinaza (jak) | |
| CA2917193A1 (en) | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators | |
| IL300289A (en) | Compounds, preparations and methods | |
| TWI712598B (zh) | 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途 | |
| CN104619702A (zh) | Ccr2的稠合环戊基拮抗剂 | |
| JP2018525372A (ja) | 呼吸器合胞体ウイルス阻害剤 | |
| JP2025508323A (ja) | Cdk4/6キナーゼの阻害薬 | |
| WO2021202796A1 (en) | Pyrrolidine-pyrazoles as pyruvate kinase activators | |
| EA050666B1 (ru) | Соединения и композиции для лечения заболеваний, связанных с коронавирусной инфекцией | |
| CN117651699A (zh) | 用于治疗冠状病毒相关疾病的化合物和组合物 | |
| HK40012561B (en) | Heteroaryl compounds and their use as mer inhibitors | |
| HK1243063B (zh) | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物 | |
| HK1204322B (en) | Inhibitors of influenza viruses replication | |
| HK1169326B (en) | Inhibitors of influenza viruses replication |